Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis

Diabetes Technology and Therapeutics

Volumn 12, Issue 10, 2010, Pages 749-753

  Mirani, Marco ^a   Berra, Cesare ^a   Finazzi, Silvia ^b   Calvetta, Albania ^b   Radaelli, Maria Grazia ^a   Favareto, Flavia ^a   Graziani, Giorgio ^b   Badalamenti, Salvatore ^b  

^a Section of Nutrition/Metabolism   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BIOSENSOR; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTINUOUS GLUCOSE MONITORING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICRODIALYSIS; MIDDLE AGED; MONITORING, AMBULATORY; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 77957943049     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0052     Document Type: Article

References (24)

1. U.S. Renal Data System: USRDS Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2007.
2. Tascona D, Ross Morton A, Toffelmire EB, Holland DC, Iliescu EA: Adequacy of glycemic control in hemodialysis patients with diabetes. Diabetes Care 2006;29:2247-2251.
3. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K: A1c and survival in maintenance hemodialysis patients. Diabetes Care 2007;30:1049-1055.
4. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278.
5. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-389.
6. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
7. Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG: Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 1996;13:514-519.
8. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-1862.
9. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
10. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354.
11. Colette C, Monnier L: Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007;39:683-686.
12. Riveline JP, Teynie J, Belmouaz S, Franc S, Dardari D, Bauwens M, Caudwell V, Ragot S, Bridoux F, Charpentier G, Marechaud R, Hadjadj S: Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009; 24:2866-2871.
13. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, Frost G, Turner JJ: Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009;32:1137-1142.
14. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19: 644-655.
15. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC: Epidemiology of dialysis patients and heart failure patients. Semin Nephrol 2006;26:118-133.
16. Weber C, Schnell O: The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009;10:623-633.
17. Ceriello A: The possible role of postprandial hyperglycemia in the pathogenesis of diabetic complications. Diabetologia 2003;46(Suppl 1):M9-M16.
18. Gallagher A, Home PD: The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with type 2 diabetes. Diabetes Res Clin Pract 2005:67:196-203.
19. De Boer MJ, Miedema K, Casparie AF: Glycosylated haemoglobin in renal failure. Diabetologia 1980;18:437-440.
20. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving haemodialysis. Am J Kidney Dis 2002;39:297-307.
21. Monnier L, Colette C, Owens D: Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008;6: 1094-1100.
22. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-2379.
23. Himmelfarb J: Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009;6: 636-643.
24. Iglesias P, Diez JJ: Insulin therapy in renal disease. Diabetes Obes Metab 2008;10:811-823.